Lyra Therapeutics Inc

Lyra Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing anti-inflammatory therapies for chronic rhinosinusitis. Its technology delivers medicines directly to affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix in Phase III clinical trials for chronic rhinosinusitis (CRS), and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.